Search

everythinglearnresearchcommunity

for

Search:↓

Triamcinolone acetonide therapy for hair loss may cause a skin condition called linear lichen planus.

Fexofenadine may help treat alopecia areata.

Vitamin D receptor gene variations are not linked to alopecia areata.

Interferon gamma alone can't cause alopecia areata in C3H/HeJ mice.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Alopecia areata leads to significantly higher healthcare costs due to more doctor visits and prescriptions.

Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.

Dupilumab for skin problems might reactivate hair loss in some patients.

Certain IL-18 gene variations may increase the risk of alopecia areata.

Platelet-rich plasma and microneedling could potentially help hair growth in people with alopecia areata, but more research is needed.

Higher concentrations of dithranol can help regrow hair in severe alopecia areata.

Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.

Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.

A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Low vitamin D levels are common in people with Alopecia Areata.

White hair regrowth in alopecia areata may be more common than thought.

The SNP rs6457452 is linked to a higher risk of alopecia areata in Koreans.

The MAGE3 hypothesis for alopecia areata did not lead to a significant breakthrough.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.

A 16-year-old boy had pernicious anemia, autoimmune hemolytic anemia, and later developed alopecia areata.

Topical 1% sildenafil is not recommended for treating alopecia areata in children.

Topical diphencyprone helped regrow hair in mice and rats with a condition similar to human hair loss.

A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.

Cases of alopecia areata and its impact on life quality rose globally, but when adjusted for age, the rates decreased, especially in poorer regions.